Medtronic plc logo

Medtronic plc

MDT

NYSEHealthcareMedical - Devices

Latest quote

$93.36

+$1.05 · +1.14%

Aug 21, 3:55 PM ET

MDT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

84

Deep Value

Momentum

43

Neutral

Sentiment

65

Bullish

Risk resilience

70

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
IE
CEO
Geoffrey Straub Martha
Listed since
May 2, 1973
Employees
95,000

Market position

Volume
7.49M
0.81× average
Average volume
9.3M
Average daily volume
Market cap
119.49B USD
Beta
0.57
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
132.81B USD
P/E (TTM)
24.89×
P/B (TTM)
2.42×
P/S (TTM)
3.29×
EV / EBITDA
13.54×
Earnings yield
4.49%
Free cash flow yield
5.08%
Dividend yield
3.05%

Profitability & efficiency

Gross margin
65.02%
Operating margin
17.78%
Net margin
13.20%
Return on equity
9.70%
Return on assets
5.16%
Return on invested capital
6.13%

Financial health

Debt / equity
0.57×
Current ratio
2.13×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends74%51%28%6%Gross margin, FY2022: 67.98%Gross margin, FY2023: 65.67%Gross margin, FY2024: 65.34%Gross margin, FY2025: 65.32%Gross margin, FY2026: 65.02%Operating margin, FY2022: 18.15%Operating margin, FY2023: 17.56%Operating margin, FY2024: 15.89%Operating margin, FY2025: 17.76%Operating margin, FY2026: 17.78%Net margin, FY2022: 15.90%Net margin, FY2023: 12.03%Net margin, FY2024: 11.36%Net margin, FY2025: 13.90%Net margin, FY2026: 13.20%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 67.98%. Gross margin FY2023 65.67%. Gross margin FY2024 65.34%. Gross margin FY2025 65.32%. Gross margin FY2026 65.02%. Operating margin FY2022 18.15%. Operating margin FY2023 17.56%. Operating margin FY2024 15.89%. Operating margin FY2025 17.76%. Operating margin FY2026 17.78%. Net margin FY2022 15.90%. Net margin FY2023 12.03%. Net margin FY2024 11.36%. Net margin FY2025 13.90%. Net margin FY2026 13.20%.

Income trends

Revenue

36.36B USD+8.43%

Operating income

6.47B USD+8.60%

Net income

4.8B USD+2.96%
Income trends across reported periods39.63B USD26.56B USD13.48B USD407.2M USDRevenue, FY2022: 31.69B USDRevenue, FY2023: 31.23B USDRevenue, FY2024: 32.36B USDRevenue, FY2025: 33.54B USDRevenue, FY2026: 36.36B USDOperating income, FY2022: 5.75B USDOperating income, FY2023: 5.49B USDOperating income, FY2024: 5.14B USDOperating income, FY2025: 5.96B USDOperating income, FY2026: 6.47B USDNet income, FY2022: 5.04B USDNet income, FY2023: 3.76B USDNet income, FY2024: 3.68B USDNet income, FY2025: 4.66B USDNet income, FY2026: 4.8B USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 31.69B USD. Revenue FY2023 31.23B USD. Revenue FY2024 32.36B USD. Revenue FY2025 33.54B USD. Revenue FY2026 36.36B USD. Operating income FY2022 5.75B USD. Operating income FY2023 5.49B USD. Operating income FY2024 5.14B USD. Operating income FY2025 5.96B USD. Operating income FY2026 6.47B USD. Net income FY2022 5.04B USD. Net income FY2023 3.76B USD. Net income FY2024 3.68B USD. Net income FY2025 4.66B USD. Net income FY2026 4.8B USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue36.36B USD33.54B USD32.36B USD31.23B USD31.69B USD
Cost of goods sold12.72B USD11.63B USD11.22B USD10.72B USD10.15B USD
Gross profit23.64B USD21.91B USD21.15B USD20.51B USD21.54B USD
Research and development2.87B USD2.73B USD2.74B USD2.7B USD2.75B USD
Selling, general, and administrative11.78B USD10.85B USD10.74B USD10.42B USD10.29B USD
Operating expenses17.18B USD15.95B USD16B USD15.02B USD15.79B USD
Interest expense715M USD729M USD719M USD636M USD553M USD
Depreciation and amortization2.96B USD2.86B USD2.65B USD2.7B USD2.71B USD
Operating income6.47B USD5.96B USD5.14B USD5.49B USD5.75B USD
Net income4.8B USD4.66B USD3.68B USD3.76B USD5.04B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+2.38%
11 comparable reports
Latest EPS result
1.55
Estimate 1.54 · Beat by 0.65%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.681.511.341.17Q4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 19, 2024: actual 1.26, estimate 1.25, surprise +0.80%, Beat. Q1 2025, reported Feb 18, 2025: actual 1.39, estimate 1.36, surprise +2.21%, Beat. Q2 2025, reported May 21, 2025: actual 1.62, estimate 1.58, surprise +2.53%, Beat. Q3 2025, reported Aug 19, 2025: actual 1.26, estimate 1.23, surprise +2.44%, Beat. Q4 2025, reported Nov 18, 2025: actual 1.36, estimate 1.31, surprise +3.82%, Beat. Q1 2026, reported Feb 17, 2026: actual 1.36, estimate 1.34, surprise +1.49%, Beat. Q2 2026, reported Jun 3, 2026: actual 1.55, estimate 1.54, surprise +0.65%, Beat. Q3 2026, reported Sep 1, 2026: actual —, estimate 1.39, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.2B9.43B8.65B7.88BQ4 '24BeatQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 19, 2024: actual 8.4B USD, estimate 8.27B USD, surprise +1.55%, Beat. Q1 2025, reported Feb 18, 2025: actual 8.29B USD, estimate 8.33B USD, surprise -0.42%, Miss. Q2 2025, reported May 21, 2025: actual 8.93B USD, estimate 8.82B USD, surprise +1.23%, Beat. Q3 2025, reported Aug 19, 2025: actual 8.58B USD, estimate 8.38B USD, surprise +2.38%, Beat. Q4 2025, reported Nov 18, 2025: actual 8.96B USD, estimate 8.87B USD, surprise +1.06%, Beat. Q1 2026, reported Feb 17, 2026: actual 9.02B USD, estimate 8.91B USD, surprise +1.19%, Beat. Q2 2026, reported Jun 3, 2026: actual 9.81B USD, estimate 9.62B USD, surprise +1.94%, Beat. Q3 2026, reported Sep 1, 2026: actual —, estimate 9.55B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

51 ratings
Strong buy12%
Buy3059%
Hold2039%
Sell00%
Strong sell00%

MDT news

MDT peers

ETFs holding MDT

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research MDT

research.disclaimer